ClinicalTrials.gg
CompletedNCT04530981Updated Sep 19, 2024

A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST

A Phase 1 interventional study of Ripretinib and Repaglinide in GIST - Gastrointestinal Stromal Tumor, sponsored by Deciphera Pharmaceuticals, LLC. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Deciphera Pharmaceuticals, LLC (part of Ono Pharmaceutical Co. Ltd) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
13
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd — 2 open to participants now, 5 under way, 2 of them phase 3. Gastrointestinal Stromal Tumors · Ono Pharmaceutical Co. Ltd.

Started
2021
with 1 other
Phase 1
3 of 10
1 open now
Registered
5th of 10
by date

Among the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, this one is one of 2 that started in 2021, is one of 3 in phase 1, and was the 5th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

2 of the 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Gastrointestinal Stromal Tumors by Ono Pharmaceutical Co. Ltd, or all of them as a file.
02

Study summary

Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Substrate

03

Conditions studied

  • GIST - Gastrointestinal Stromal Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients ≥18 years of age.
  2. Patients must have a histologic diagnosis of GIST.
  3. Patients must have GIST that has progressed on or have intolerance to at least 2 lines of prior TKI therapies.
  4. Patients must have an performance score of ≤ 2.
  5. If a female of , must have a negative pregnancy test prior to enrollment and agree to follow the requirements.
  6. Adequate organ and bone marrow function.

Exclusion criteria

Exclusion Criteria:

  1. Received prior anticancer or other therapy within 28 days or 5× the half-life prior to the first dose.
  2. Prior treatment with ripretinib.
  3. Patients who have had prior repaglinide treatment within 14 days prior to Cycle 1 Day 1.
  4. History or presence of cardiovascular abnormalities.
  5. Gastrointestinal abnormalities including but not limited to:

    • inability to take oral medication,
    • malabsorption syndromes,
    • requirement for intravenous alimentation.
  6. Patients who have type 1 or type 2 diabetes.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Repaglinide 0.5 mg + Ripretinib 150 mg QD

    A single dose of repaglinide 0.5 mg (1 × 0.5-mg tablet) will be administered orally on Cycle 1 Day 1 and Cycle 1 Day 15. Ripretinib 150 mg QD (3 × 50-mg tablets) will be administered orally from Day 2 through Day 28 for Cycle 1 and will be administered continuously from Cycle 2 until disease progression as assessed by the Investigator, unacceptable toxicity, or withdrawal of consent.

    Drug: Ripretinib · Drug: Repaglinide

Interventions

  • Oral KIT/PDGFRA kinase inhibitor

    Also known as: QINLOCK

  • Oral antihyperglycemic agent

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration for Repaglinide

    Measure the Cmax

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.

  2. Area under the concentration-time curve (AUC) from time 0 up to time t (AUC0-t) for Repaglinide

    Measure the AUC0-t

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.

  3. AUC from time 0 and extrapolated to infinity (AUC0-∞)

    Measure the AUC0-∞

    Time frame: Cycle 1 Day 1 and Cycle 1 Day 15 (pre-dose and at multiple time points [up to 24 hours] post-dose). Each cycle is 28 days.

Secondary outcomes

  1. Incidence of Adverse Events

    Adverse events \[TEAEs, SAEs\], dose reduction, dose interruption, or discontinuation, vital signs (heart rate \[beats/min\], and changes in laboratory parameters (chemistry, hematology, urinalysis, coagulation).

    Time frame: Cycle 1 through study completion (~ 12 months). Each cycle is 28 days.

07

Study locations

3 sites
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Oregon Health & Science University
    Portland, Oregon 97239, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Nov 2023, 25 months.

Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's 25 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2020
First posted
Aug 28, 2020
StartActual
Sep 22, 2021
Primary completionActual
Nov 16, 2023
CompletionActual
Jul 29, 2024
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04530981
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Sep 22, 2021
Primary completion
Nov 16, 2023
Completion
Jul 29, 2024
Last update
Sep 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ripretinib · Repaglinide

Start the discussion